Drug Profile
NNI 362
Alternative Names: NNI-362Latest Information Update: 28 Aug 2023
Price :
$50
*
At a glance
- Originator Neuronascent
- Class Antidementias; Antiparkinsonians; Small molecules
- Mechanism of Action 70 kDa ribosomal protein S6 kinase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Alzheimer's disease
Highest Development Phases
- Phase I Alzheimer's disease
- Preclinical Parkinson's disease
Most Recent Events
- 16 Jul 2023 Pharmacodynamics data from a preclinical study in Alzheimer's disease presented at the Alzheimer's Association International Conference 2023 (AAIC-2023)
- 14 Apr 2023 NNI 362 is still in phase I trials for Alzheimer disease in USA (Neuronascent pipeline, April 2023)
- 28 Nov 2022 No recent reports of development identified for phase-I development in Alzheimer's-disease(In the elderly, In volunteers, In adults) in USA (PO, Suspension)